SGLT-2 (sodium–glucose cotransporter-2) inhibitors, often referred to as gliflozins or flozins, achieved a significant milestone in 2012 with approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus (T2DM) [1,2,3]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.